Divya pharmacies have taken the licence approval for Divya Coronil Tablet and Divya Swasarivati on their traditional reported usages, and have now connected those with the modern research based clinical findings, Patanjali said.
Baba Ramdev’s Patanjali on Wednesday said that there was no difference of opinion between the company and the Ayush Ministry over its medicine – Coronil. It said that it had shared all clinical trial documents with AYUSH and the Government of India. “The ministry also agreed that Patanjali Research Foundation has appropriately worked on COVID-19 management. Now there is no difference of opinions with Ayush Ministry and Patanjali,” it said in a statement.
Patanjali further said that now it was allowed to manufacture and distribute its Divya Coronil Tablet, Divya SwasariVati and Divya AnuTila across India as per the manufacturing licenses granted by state Licensing Authority, Ayurvedic and Unani services, Government of Uttarakhand.
- COVID-19: With over 6.90 lakh cases India surpasses Russia, now third worst-hit nation after US and Brazil
- India records over 20,000 new COVID cases for third consecutive day; set to overtake Russia as third-worst hit nation
- COVID-19 in Delhi: Less patients now require hospitalisation, more recovering at home, says CM Arvind Kejriwal
However, news agency PTI reported that the AYUSH Ministry has allowed Patanjali to sell the product but not as a cure. According to the report, the ministry has only given permission to sell Patanjali’s Coronil as immunity booster and not as a medicinal cure for coronavirus.
Patanjali today defended its research and medicines and said Ayurvedic drug license and control clinical trials were two different streams. It said that all the manufacturing and distribution licenses for Ayurvedic medicines are granted on the basis of their reported traditional usages.
पूज्य @yogrishiramdev की प्रेस कांफ्रेंस के संदर्भ में प्रेस ब्रीफ हिंदी और अंग्रेजी दोनों में..!
— Tijarawala SK (@tijarawala) July 1, 2020
“Clinical studies are then conducted on those medicines, in some cases. In the similar way, Patanjali’s Divya pharmacies have taken the licence approval for Divya Coronil Tablet and Divya Swasarivati on their traditional reported usages, and have now connected those with the modern research based clinical findings,” Patanjali said.
Last month, Patanjali Research Institute-Haridwar and NIMS University-Jaipur had jointly conducted randomised, placebo-controlled double-blinded clinical trials on Covid-19 positive patients, it said in a release. Patanjali claims that this trial was approved by the Institutional Ethics Committee and duly registered at Clinical Trial Registry-India. “In this trial, 95 patients (in the 15-65 years’ age range, male-female both, asymptomatic, mild to moderate) participated on the written consent basis,” it said.
According to the ayurvedic medicine giant, 45 patients were treated with Patanjali medicines and rest 50 patients were given placebo formulations. “The COVID-19 patent group that received Patanjali medicines, showed 67% recovery in 3 days and 100% recovery in 7 days of treatments – all 45 patients became COVID-19 negative,” Patanjali said in a detailed statement.
On June 23, Baba Ramdev and Patanjali MD Acharya Balkrishna put out the results of clinical trials and launched a medicine kit – Coronil. Hours after the launch of Coronil, Ayush Ministry denied having any information about the trials or medicines claimed to be possible treatment for coronavirus. Soon, the ministry asked for relevant documents and asked Patanjali to stop advertising until the drug was cleared by the competent authority.